ATE404218T1 - Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren - Google Patents
Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahrenInfo
- Publication number
- ATE404218T1 ATE404218T1 AT01927074T AT01927074T ATE404218T1 AT E404218 T1 ATE404218 T1 AT E404218T1 AT 01927074 T AT01927074 T AT 01927074T AT 01927074 T AT01927074 T AT 01927074T AT E404218 T1 ATE404218 T1 AT E404218T1
- Authority
- AT
- Austria
- Prior art keywords
- intracellular pathogens
- methods
- recombinant
- vaccines
- immunotherapeutics
- Prior art date
Links
- 230000003834 intracellular effect Effects 0.000 title abstract 7
- 244000052769 pathogen Species 0.000 title abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 230000001355 anti-mycobacterial effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/550,468 US6471967B1 (en) | 2000-04-17 | 2000-04-17 | Recombinant intracellular pathogen vaccines and methods for use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE404218T1 true ATE404218T1 (de) | 2008-08-15 |
Family
ID=24197308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01927074T ATE404218T1 (de) | 2000-04-17 | 2001-04-16 | Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6471967B1 (de) |
| EP (1) | EP1274453B1 (de) |
| JP (1) | JP4868682B2 (de) |
| CN (1) | CN1437479B (de) |
| AT (1) | ATE404218T1 (de) |
| AU (1) | AU5355801A (de) |
| CA (1) | CA2406225C (de) |
| DE (1) | DE60135318D1 (de) |
| ES (1) | ES2315281T3 (de) |
| RU (1) | RU2266132C2 (de) |
| WO (1) | WO2001078774A2 (de) |
| ZA (1) | ZA200209304B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300660B2 (en) * | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US6924118B2 (en) * | 2000-04-17 | 2005-08-02 | The Regents Of The University Of California | Recombinant intracellular pathogen immunogenic compositions and methods for use |
| CA2481108C (en) | 2002-04-16 | 2013-05-28 | Jun Liu | Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase |
| US8383132B2 (en) * | 2003-10-16 | 2013-02-26 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
| WO2007121194A1 (en) * | 2006-04-10 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
| DK2206514T3 (da) * | 2003-10-16 | 2014-04-22 | Univ California | Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse |
| CA2589204C (en) * | 2004-12-01 | 2013-10-29 | Aeras Global Tb Vaccine Foundation | Recombinant bcg strains with enhanced ability to escape the endosome |
| GB0709373D0 (en) * | 2007-05-16 | 2007-06-27 | Thrombosis Res Inst | BCG-based anti-atheroma vaccine |
| US8647641B2 (en) * | 2008-10-20 | 2014-02-11 | University Of Zurich | Mycobacterium tuberculosis vaccine |
| US20130101614A1 (en) * | 2010-06-15 | 2013-04-25 | The Regents Of The University Of California | Novel live recombinant booster vaccine against tuberculosis |
| KR101832019B1 (ko) * | 2010-12-21 | 2018-02-23 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 백신으로서의 재조합 마이코박테리움 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988006626A1 (en) | 1987-03-02 | 1988-09-07 | Whitehead Institute For Biomedical Research | Recombinant mycobacterial vaccine |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| US5591632A (en) | 1987-03-02 | 1997-01-07 | Beth Israel Hospital | Recombinant BCG |
| US5807723A (en) | 1987-03-02 | 1998-09-15 | Whitehead Institute For Biomedical Research | Homologously recombinant slow growing mycobacteria and uses therefor |
| JP2903414B2 (ja) | 1989-05-31 | 1999-06-07 | 味の素株式会社 | 抗酸菌分泌発現ベクター及び抗酸菌 |
| AU681572B2 (en) | 1991-10-21 | 1997-09-04 | Med Immune, Inc. | Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins |
| US5736367A (en) | 1992-03-31 | 1998-04-07 | Medimmune, Inc. | Vectors and prokaryotes which autocatalytically delete antibiotic resistance |
| US5679515A (en) | 1994-10-03 | 1997-10-21 | Pathogenesis Corporation | Mycobacterial reporter strains and uses thereof |
| US5700683A (en) | 1995-02-17 | 1997-12-23 | Pathogenesis Corporation | Virulence-attenuating genetic deletions deleted from mycobacterium BCG |
| US5869057A (en) | 1995-06-07 | 1999-02-09 | Rock; Edwin P. | Recombinant vaccines to break self-tolerance |
-
2000
- 2000-04-17 US US09/550,468 patent/US6471967B1/en not_active Expired - Lifetime
-
2001
- 2001-04-16 WO PCT/US2001/012380 patent/WO2001078774A2/en active Application Filing
- 2001-04-16 CA CA2406225A patent/CA2406225C/en not_active Expired - Fee Related
- 2001-04-16 AU AU5355801A patent/AU5355801A/xx not_active Withdrawn
- 2001-04-16 EP EP01927074A patent/EP1274453B1/de not_active Expired - Lifetime
- 2001-04-16 ES ES01927074T patent/ES2315281T3/es not_active Expired - Lifetime
- 2001-04-16 AT AT01927074T patent/ATE404218T1/de not_active IP Right Cessation
- 2001-04-16 RU RU2002130716/15A patent/RU2266132C2/ru active
- 2001-04-16 JP JP2001576073A patent/JP4868682B2/ja not_active Expired - Lifetime
- 2001-04-16 DE DE60135318T patent/DE60135318D1/de not_active Expired - Lifetime
- 2001-04-16 CN CN018110045A patent/CN1437479B/zh not_active Expired - Lifetime
-
2002
- 2002-11-15 ZA ZA200209304A patent/ZA200209304B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2002130716A (ru) | 2004-03-27 |
| US6471967B1 (en) | 2002-10-29 |
| ZA200209304B (en) | 2004-08-13 |
| DE60135318D1 (de) | 2008-09-25 |
| CA2406225C (en) | 2012-06-26 |
| WO2001078774A2 (en) | 2001-10-25 |
| CA2406225A1 (en) | 2001-10-25 |
| JP2004507453A (ja) | 2004-03-11 |
| AU5355801A (en) | 2001-10-30 |
| CN1437479A (zh) | 2003-08-20 |
| JP4868682B2 (ja) | 2012-02-01 |
| EP1274453A2 (de) | 2003-01-15 |
| RU2266132C2 (ru) | 2005-12-20 |
| WO2001078774A3 (en) | 2002-03-28 |
| EP1274453B1 (de) | 2008-08-13 |
| CN1437479B (zh) | 2012-12-05 |
| ES2315281T3 (es) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60142772D1 (de) | Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält | |
| AR035586A1 (es) | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn | |
| BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
| ATE404218T1 (de) | Rekombinante bcg-impfstoffe gegen intrazelluläre pathogene und anwendungsverfahren | |
| MX2007003402A (es) | Composicion inmunogena para su uso en vacunacion contra estafilococos. | |
| EP3616716A3 (de) | Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen und verwendungen davon | |
| CY1112589T1 (el) | Ανοσογονος συνθεση που περιεχει ανοσοενισχυτικο | |
| CY1114243T1 (el) | Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων | |
| FR2814958B1 (fr) | Composition vaccinale | |
| NO20111324A1 (no) | Rekombinant MVA-virus | |
| GB0123580D0 (en) | Vaccine | |
| GB2255093A (en) | Hiv-1 core protein fragments | |
| BR9910749A (pt) | Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma | |
| IL107262A0 (en) | Oral vaccines comprising multiple emulsions and methods of preparation | |
| MX2020008454A (es) | Composicion inmunogenica que comprende antigenos estafilococicos. | |
| AU1813701A (en) | Interleukin-1 muteins useful as vaccine adjuvants | |
| CA2022420A1 (en) | Escherichia coli vaccine | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| BR112022020438A2 (pt) | Composições compreendendo três proteínas de fusão ospa para uso médico | |
| CY1107538T1 (el) | Εμβολιο μυκοπλασματος αδρανοποιημενο με σαπωνινη | |
| ATE487489T1 (de) | Rekombinante intrazellulärepathogen-immunogene zusammensetzungen und anwendungsverfahren | |
| NO20045587L (no) | Liposom vaksineformulering for finne-fisk | |
| Martínez-Gómez et al. | Protection against Toxoplasma gondii brain cyst formation in mice immunized with Toxoplasma gondii cytoskeleton proteins and Lactobacillus casei as adjuvant | |
| DK0952771T3 (da) | Hidtil ukendte saponinpræparater og anvendelser deraf | |
| AU6761301A (en) | Adjuvant composition comprising fha protein or fragment of fha protein in free form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |